Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Chapman (Bridgewater, United States of America), M. Corboz (Bridgewater, United States of America), S. Gagnon (Sherbrooke, Canada), C. Brodeur (Sherbrooke, Canada), A. Plaunt (Bridgewater, United States of America), V. Malinin (Bridgewater, United States of America), H. Gauani (Bridgewater, United States of America), D. Chun (Bridgewater, United States of America), Z. Li (Bridgewater, United States of America), D. Cipolla (Bridgewater, United States of America), W. Perkins (Bridgewater, United States of America). No evidence of desensitization to repeat dosing with treprostinil palmitil inhalation suspension (TPIS) for 32-consecutive days in hypoxia-challenged telemetered rats. 1486

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of the novel very long-acting β2-agonist carmoterol following 7 days once daily dosing: comparison with twice daily formoterol in patient with persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 665s Year: 2006 Inhalation of dry powder INS1009 (DP-INS1009) does not activate the cough reflex in guinea pigs: a comparison with nebulized treprostinil. Source: International Congress 2017 – Experimental PH Year: 2017 Repeated daily inhalations of ciclesonide, compared to single inhalation, do not lead to increased systemic exposure Source: Eur Respir J 2003; 22: Suppl. 45, 282s Year: 2003 Bronchodilator response of single dose of tiotropium (Tio) plus formoterol (Formo) versus four doses of ipratopium (Ipra) plus salbutamol (Salb) over 24 hours in subjects with moderate-to-severe stable COPD Source: Annual Congress 2008 - Diagnosing, monitoring and treating respiratory diseases in primary care Year: 2008 Effects of intratracheal pf-00610355, an inhaled β2 adrenoceptor agonist, in anaesthetised animals Source: Annual Congress 2009 - New bronchodilators Year: 2009 Inhaled liposomal treprostinil (L606) shows extended release in healthy volunteer, as well as prolongs pharmacological effect in hypoxia-induced rat. Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020 Dose- and exposure response analysis of glycopyrrolate (GP) metered dose inhaler (MDI) to support optimal dosing in patients with COPD for combination product development Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010 Bioequivalence of two ciclesonide dosing regimen (4 puffs of 200μg vs. 16 puffs of 50μg using an MDI) Source: Eur Respir J 2002; 20: Suppl. 38, 109s Year: 2002 Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist (LAMA), in patients with COPD Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011 Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011 Formoterol 6 μg and 12 μg delivered via a new multi-dose dry powder inhaler has a rapid onset of action with a duration of at least 12 hours Source: Eur Respir J 2002; 20: Suppl. 38, 501s Year: 2002 Compound X – an inhaled β2 agonist with equivalent potency and superior duration of action (DOA)/ therapeutic index (TI) to salmeterol in the anaesthetised dog model of bronchoconstriction Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008 Bioequivalence of two ciclesonide dosing regimens (4 puffs of 200μg vs. 8 puffs of 100μg using an MDI) Source: Eur Respir J 2002; 20: Suppl. 38, 304s Year: 2002 Single dose of of tiotropium bromide (18 mcg) produces a similar bronchodilator response as two doses of formoterol fumarate (12 mcg ) over 24 hours in subjects with moderate-to-severe asthma Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010 Comparison of response to lipopolysaccharide administered by intravenous, orotracheal and inhaled routes in rats Source: Eur Respir J 2007; 30: Suppl. 51, 135s Year: 2007 Safety and tolerability of the novel very long acting β2-agonist Carmoterol given as a 2μg qd dose; 8 days comparison with formoterol and placebo in patients with persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 665s Year: 2006 Pharmacokinetics (PK) of a single dose AZD7594 administered intravenously (IV), orally, and inhaled via two dry powder inhalers (DPI) and a pressurized metered-dose inhaler (pMDI) Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017 Potency and duration of action of R,R-glycopyrrolate (RRG) on acetylcholine (ACh) induced bronchoconstriction as compared to tiotropium (TIO) in unrestrained conscious mice Source: Eur Respir J 2005; 26: Suppl. 49, 217s Year: 2005 Synergistic bronchoprotective activity of the long-acting beta 2-agonist olodaterol with tiotropium (long-acting M3 antagonist) and ciclesonide (inhaled steroid) on the ovalbumin-induced bronchoconstriction in anaesthetized guinea pigs Source: Annual Congress 2011 - Understanding disease and drug mechanisms Year: 2011 Effects of intravenous injection of TNF-a on the respiratory system of anesthetized rats Source: International Congress 2017 – Respiratory and exercise physiology Year: 2017